Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

News Daily News

Side Effects of Statins Might Be Overstated: CTT Collaboration

Michael O'Riordan

February 12, 2026

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

L.A. McKeown

January 16, 2026

News Daily News

Etripamil Nasal Spray Gains FDA Approval for Acute Paroxysmal SVT

Todd Neale

December 15, 2025

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Michael O'Riordan

February 12, 2025

News Daily News

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Michael O'Riordan

September 16, 2024

News Daily News

FDA Grants MACE Reduction Indication for Semaglutide

Todd Neale

March 08, 2024

News Daily News

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

Shelley Wood

May 09, 2023

News Daily News

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

Michael O'Riordan

January 17, 2023

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Yael L. Maxwell

July 09, 2021

News Daily News

Papers Probe Temporal Link Between COVID-19 Vaccines and Myocarditis

Michael O'Riordan

June 17, 2021

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Daily News

Xience Cleared in Europe for 1-Month DAPT in High-Bleeding-Risk Patients

Shelley Wood

April 06, 2021

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Daily News

FDA Approves Harmony TPV for Pulmonary-Valve Regurgitation in Congenital HD

Yael L. Maxwell

March 26, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Daily News

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

Shelley Wood

June 01, 2020

Advertisement

Side Effects of Statins Might Be Overstated: CTT Collaboration

January 2026 Dispatch for the CV Team

Etripamil Nasal Spray Gains FDA Approval for Acute Paroxysmal SVT

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Little Pre- and Postmarket Testing for Most Recalled CV Devices

FDA Grants MACE Reduction Indication for Semaglutide

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

FDA Approves Empagliflozin for Treatment of HFpEF

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Papers Probe Temporal Link Between COVID-19 Vaccines and Myocarditis

FDA Approves Dapagliflozin for CKD Patients

Xience Cleared in Europe for 1-Month DAPT in High-Bleeding-Risk Patients

Roughly 80% of ESC Guideline Writers Have Financial COIs

FDA Approves Harmony TPV for Pulmonary-Valve Regurgitation in Congenital HD

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content